ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 890

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate

Roy Fleischmann1, Aileen L. Pangan2, Eduardo Mysler3, Louis Bessette4, Charles Peterfy5, Patrick Durez6, Andrew Ostor7, Yihan Li2, Yijie Zhou2, Ahmed A. Othman2, In-Ho Song8 and Mark C. Genovese9, 1University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, 2AbbVie, Inc., North Chicago, IL, 3Organización Medica de Investigación, Buenos Aires, Argentina, 4Laval University, Québec, QC, Canada, 5Spire Sciences LLC, Boca Raton, FL, 6Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 7Cabrini Medical Center, Malvern, Australia, 8AbbVie, Inc., north chicago, IL, 9Stanford University Medical Center, Palo Alto, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Adalimumab, Janus kinase (JAK), radiography and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S087 ACR Abstract: RA–Treatments I: JAK Inhibitors (886–891)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: To assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib (UPA), a JAK1- selective inhibitor, vs placebo (PBO) and active comparator, originator adalimumab (ADA), in patients (pts) with active rheumatoid arthritis (RA) continuing on prior methotrexate (MTX).

 

Methods: In SELECT–COMPARE, pts with active RA despite MTX were randomized 2:2:1 to once-daily (QD) UPA 15mg, PBO, or ADA 40mg every other week (wk) in a double-blind manner, while continuing stable background MTX. Primary endpoints were ACR20 and the proportion of pts achieving DAS28CRP<2.6 (NRI) at Wk12. Key secondary endpoints included non-inferiority (and superiority) of UPA vs ADA at Wk12 (for ACR50, DAS28CRP≤3.2, change from BL (Δ) in Pain, and ΔHAQ-DI), and radiographic inhibition (ΔmTSS) for UPA vs PBO at Wk26. Pts with <20% improvement in TJC and SJC were rescued between Wks14- 26 (from PBO to UPA, UPA to ADA, or ADA to UPA).

                        

Results:

Of 1629 randomized pts, 91% completed Wk26 (including rescued pts). BL characteristics were similar across arms. All primary and key secondary endpoints were met.  At Wk12, significantly more pts on UPA vs PBO achieved ACR20 (70.5% vs 36.4%) and DAS28CRP<2.6 (28.7% vs 6.1%) (Table 1). Superiority was met for UPA vs ADA at Wk12 for ACR50 (45.2% vs 29.1%), DAS28CRP≤3.2 (45.0% vs 28.7%), ΔPain (-31.76 vs -25.31) and ΔHAQ-DI (-0.60 vs -0.49). These differences were maintained through Wk26.  At Wk26, pts on UPA vs PBO had significantly less radiographic progression (ΔmTSS, 0.24 vs 0.92), and significantly more pts had no radiographic progression (ΔmTSS ≤0) (83.5% vs. 76.0%). At Wk26, more pts on UPA vs PBO or ADA achieved low disease activity or remission by various criteria (nominal p<.001).

Up to Wk26, the proportion of pts with adverse events (AEs) and serious infections, censored at rescue, was higher for UPA vs PBO but similar vs ADA (Table 2).  The proportion of pts with SAEs and AEs leading to discontinuation for UPA was numerically higher vs PBO and lower vs ADA. Herpes Zoster was numerically higher in UPA vs ADA and PBO.  Three malignancies, 5 major adverse cardiovascular events, and 4 deaths were reported, none on UPA. Six venous thromboembolic events (VTEs) were reported (1 on PBO, 2 on UPA and 3 on ADA).  For pts who were rescued, no deaths, adjudicated MACE, or adjudicated VTE were observed between rescue and Wk26.

Conclusion: UPA 15mg QD showed superiority on improvement in RA signs & symptoms vs PBO and ADA in this MTX-IR population. Radiographic progression was significantly lower with UPA vs PBO. Safety events were consistent with Ph 2 and 3 studies in RA to date.


Disclosure: R. Fleischmann, AbbVie, Lilly, Pfizer, Gilead, 2,AbbVie, Lilly, Pfizer, Gilead, 5; A. L. Pangan, AbbVie Inc., 1,AbbVie Inc., 3; E. Mysler, AbbVie, Lilly, Pfizer, Roche, BMS, Sandoz, 2,AbbVie, Lilly, Pfizer, Roche, BMS, Sandoz, 5; L. Bessette, Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, 2, 5, 8; C. Peterfy, Spire Sciences, Inc, 3,Spire Sciences, Inc, 1,Amgen, Bristol-Myers Squibb; consultant: Centrexion, Crescendo Bioscience, Daiichi Sankyo, EMD Serono, Five Prime, Flexion Therapeutics, Genentech, Gilead, GlaxoSmithKline, Pfizer, Plexikkon, Regeneron, Roche, SetPoint., 8; P. Durez, BMS, Lilly, Sanofi, Pfizer, 8; A. Ostor, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Eli Lilly, Novartis, 2,BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Eli Lilly, Novartis, 5,BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Eli Lilly, Novartis, 8; Y. Li, AbbVie Inc., 1,AbbVie Inc., 3; Y. Zhou, AbbVie Inc., 1,AbbVie Inc., 3; A. A. Othman, AbbVie Inc., 1,AbbVie Inc., 3; I. H. Song, AbbVie, Inc., 1,AbbVie, Inc., 3; M. C. Genovese, AbbVie, Lilly, Pfizer, Galapagos, Gilead, 5,AbbVie, Lilly, Pfizer, Galapagos, Gilead, 2.

To cite this abstract in AMA style:

Fleischmann R, Pangan AL, Mysler E, Bessette L, Peterfy C, Durez P, Ostor A, Li Y, Zhou Y, Othman AA, Song IH, Genovese MC. A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/a-phase-3-randomized-double-blind-study-comparing-upadacitinib-to-placebo-and-to-adalimumab-in-patients-with-active-rheumatoid-arthritis-with-inadequate-response-to-methotrexate/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-phase-3-randomized-double-blind-study-comparing-upadacitinib-to-placebo-and-to-adalimumab-in-patients-with-active-rheumatoid-arthritis-with-inadequate-response-to-methotrexate/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology